Abstract:Aim EphB3 and dysadherin are involved in tumorigenesis and progression of many neoplasms. However, the roles of EphB3 and dysadherin in extrahepatic cholangiocarcinoma (ECC) remain to be revealed. In this study, we aimed to evaluate the expression of EphB3 and dysadherin, and investigate their clinicopathological significance in ECC. Methods We examined EphB3 and dysadherin expression in 100 ECC, 30 peritumoral tissues, 10 adenoma and 15 normal biliary tract tissues using EnVision immunohistochemistry. The relationship between EphB3 or dysadherin expression and clinicopathological features was evaluated using the χ2 test or Fisher’s exact test. The overall survival of ECC patients was analyzed using Kaplan-Meier univariate survival analysis and Log rank tests. Results We found that EphB3 expression was significantly down-regulated and dysadherin expression was significantly up-regulated in ECC tissues compared with normal tissues (P < 0.01). EphB3 expression was negatively correlated with dysadherin expression in ECC (P < 0.01). The positive rate of EphB3 expression and negative rate of dysadherin expression was significantly higher in patients with well-differentiated type, no lymph node metastasis, no surrounding tissues and organs invasion, early TNM stages (I + II) and radical resection (P < 0.01). The survival of ECC patients with positive EphB3 or negative dysadherin expression was significantly longer than patients with negative EphB3 or positive dysadherin expression (P < 0.01). Cox multivariate analysis demonstrated that negative EphB3 or positive dysadherin expression were independent poor prognostic factors in ECC patients. The ROC curves suggested that EphB3 and dysadherin combined diagnostic efficacy (AUC=0.688, 95%CI: 0.603-0.772) was significantly higher EphB3 diagnostic efficacy (AUC=0.654, 95%CI: 0.564-0.743) or dysadherin diagnostic efficacy (AUC=0.648, 95%CI: 0.558-0.737) alone. Conclusion EphB3 and dysadherin are involved in the carcinogenesis and progression of ECC, and ECC patients with negative EphB3 or positive dysadherin expression have a poor prognosis.

Clinical significance of decreased expression of EphB6 receptor tyrosine kinase in colorectal carcinoma

Expression and Significance of EphB6 Protein in Colorectal Carcinoma

Loss of EphB6 protein expression in human colorectal cancer correlates with poor prognosis

Expression of EphA1 Gene in colorectal Cancers and Its Clinical Significance

Differentail expression of EphB1 mRNA and protein in colorectal cancer and its clinicopathologic significance

Reduced Expression of EphA5 is Associated with Lymph Node Metastasis, Advanced TNM Stage, and Poor Prognosis in Colorectal Carcinoma.

EphB1 is Underexpressed in Poorly Differentiated Colorectal Cancers.

Reduced EphB6 Protein in Gastric Carcinoma and Associated Lymph Nodes Suggests EphB6 As a Gastric Tumor and Metastasis Inhibitor.

High Expression of EphB6 Protein in Tongue Squamous Cell Carcinoma is Associated with a Poor Outcome.

Downregulation of EphA1 in colorectal carcinomas correlates with invasion and metastasis.

Expression and its clinical significance of receptor tyrosine kinase EphB1 in gastric carcinoma

High Expression of EphA4 is Associated with Invasion and Lymph Node Metastasis in Colorectal Carcinomas.

Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours

Expression and Clinical Significance of EPHB3 Receptor in Colorectal Carcinoma

Expression of EphB6 in Ovarian Serous Carcinoma is Associated with Grade, TNM Stage and Survival.

Receptor Tyrosine Kinase EphB3: a Prognostic Indicator in Colorectal Carcinoma

Reduced Expression of EphB2 is Significantly Associated with Nodal Metastasis in Chinese Patients with Gastric Cancer

The relationship between the expression of EphA1 in gastric carcinoma, metastasis and survival

Prognostic and Clinicopathological Significance of EphB3 and Dysadherin Expression in Extrahepatic Cholangiocarcinoma.

Loss of expression of EphB1 protein in gastric carcinoma associated with invasion and metastasis.

Decreased Expression Of Epha5 Is Associated With Fuhrman Nuclear Grade And Pathological Tumour Stage In Ccrcc